JAYSON TRIPP: Open Payments
NPI 1578053138 · ROSWELL, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,030 in 201 payments from 19 companies in 2025. Trend: 2023 $3,125 · 2024 $3,612 · 2025 $4,030
Food & beverage: $4,030
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 26 | $616 |
| Otsuka America Pharmaceutical, Inc. | 29 | $537 |
| ABBVIE INC. | 29 | $464 |
| Corium, LLC | 21 | $453 |
| Axsome Therapeutics, Inc. | 13 | $355 |
| Vanda Pharmaceuticals Inc. | 13 | $351 |
| Supernus Pharmaceuticals, Inc. | 9 | $165 |
| Teva Pharmaceuticals USA, Inc. | 7 | $154 |
| Collegium Pharmaceutical, Inc. | 11 | $148 |
| Neurocrine BioSciences, Inc. | 3 | $146 |
Products named: CAPLYTA, VRAYLAR, Azstarys, REXULTI, FANAPT, Auvelity, ABILIFY ASIMTUFII, Qelbree.
Industry payments across GA — which companies pay providers there.
